Submit Deal

AUGUSTINE THERAPEUTICS NV

HQ - Leuven

Summary

Augustine Therapeutics is a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 65 M

Avg. Deal Size£ 65 M

Market Context

Senior Management

Gerhard Koenig
CEO

Sort

24 Mar 2025|Belgium|Biotechnology

Target: AUGUSTINE THERAPEUTICS NV

Bidder: V-BIO VENTURES

6 Service Providers

2 Target | 4 Bidder

9 Dealmakers

2 Target | 9 Bidder

£ 65 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy